CA
NAUT icon

Crewe Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Crewe Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Hold
136,052
– – 0.02% 205
2026
Q1 		$528K Hold
136,052
– – 0.05% 122
2025
Q4 		$265K Hold
136,052
– – 0.02% 183
2025
Q3 		$115K Buy
+136,052
New +$100K 0.01% 269

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Crewe Advisors's NAUT Position: Q2 2026 in Review

Crewe Advisors held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 136,052 shares worth $254K. The position accounts for 0.02% of the portfolio, ranked #205.

Crewe Advisors first reported a position in NAUT in Q3 2025 and has held it in 4 quarters since. The position peaked at $528K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Crewe Advisors held 136,052 shares of Nautilus Biotechnolgy worth $254K as of Q2 2026.
  • Crewe Advisors left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up 0.02% of Crewe Advisors's portfolio in Q2 2026, its #205 holding.
  • Crewe Advisors first reported a position in Nautilus Biotechnolgy in Q3 2025 and has held it in 4 quarters since.
  • Crewe Advisors's Nautilus Biotechnolgy position peaked at $528K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.